GenSight Biologics obtains €15 million in financing through a bond issuance from Kreos Capital and a reserved capital increase from Sofinnova and 3SBio

38th Annual J.P. Morgan Healthcare Conference, San Francisco (CA), USA

GenSight Biologics Reports its Cash Position as of September 30, 2019 and Provides Operational Update

GenSight Biologics Appoints Magali Taiel as Chief Medical Officer

GenSight Biologics to present new GS010 data at the 2019 Annual Meeting of the American Academy of Ophthalmology

GenSight Biologics integrates the Enternext® PEA-PME 150 index by Euronext

GenSight Biologics Reports Interim Financial Results for the First Half of 2019 and Provides Operational Update

GenSight Biologics expands its Board of Directors with the appointments of Maritza McIntyre and Sofinnova Partners

BIO International Convention, Philadelphia, PA (US)

GenSight Biologics Reports Full Year 2018 Financial Results